ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1425

Screening Behavior and Prevalence of Hepatitis C Virus in Mexico

Cassandra Skinner-Taylor1, Alejandro Erhard-Ramírez1, David Vega-Morales2, Jorge Esquivel-Valerio1, Diana Flores-Alvarado2, Daniel Treviño-Montes1 and Ernesto Torres-López3, 1Departamento de Medicina Interna del Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Servicio de Reumatología, Departamento de Medicina Interna del Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, Mexico, 2Rheumatology, Hospital Universitario UANL, Monterrey, Mexico, 3Inmunología del Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Servicio de Inmunología del Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, Mexico

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Hepatitis C and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects (ACR): Comorbidities, Treatment Outcomes and Mortality

Session Type: Abstract Submissions (ACR)

Background/Purpose

In some countries, the prevalence of Hepatitis C virus infection is high and sometimes the appropriate tests to detect it are not performed in a routine evaluation in patients with Rheumatoid arthritis (RA). Our aim was to study the hepatitis C virus infection prevalence in RA patients and to determine the clinical characteristics of the patients who were screened and to evaluate the behavior of the current screening.

Methods

Retrospective, Observational, non-comparative study. We reviewed all charts of RA patients seen between 2013 and 2014 in three settings. University Hospital (HU), Private Practice (PP), and Instituto Mexicano del Seguro Social (IMSS), all from Monterrey, Nuevo León,  Mexico. We select cases that met the ACR 1987 and EULAR/ ACR 2010 criteria for RA. We look for laboratory tests including rheumatoid factor, anti CCP, the screening test for hepatitis C virus and liver function tests.

Results

Eight hundred and sixty-four patients were analyzed, 312 (36.1%) of HU, 380 (44%) of IMSS and 172 (19.9%) of PP. Females 92% (n = 792). Mean age 51.6 years (age range 17-89). Anti-TNF therapy were used in 172 patients (19.9%), and the rest used DMARDs (methotrexate, sulfasalazine, hydroxychloroquine, leflunomide and chloroquine). Rheumatoid factor was positive in 63.7%. Anti CCP was positive in  69.8%. Only  197 patients(22.8%) were screened for hepatitis C. One hundred eighty-eight (95%) from PP. The main reason because they were being treated with anti-TNF agents (golimumab, adalimumab, certolizumab pegol and infliximab). In public practice, corresponding to HU, five patients were screened and at IMSS only four. There was only one positive patient (1/197) corresponding to 0.5% for the screened patients. 

Conclusion

In countries where hepatitis C virus is not endemic, as in Mexico, routine screening for HCV does not seem a regular practice for the rheumatologists, the main reason for screening in private practice was that the population was mostly being treated with anti-TNF agents, in contrast to public practice where the mainstay of treatment were DMARDs.


Disclosure:

C. Skinner-Taylor,
None;

A. Erhard-Ramírez,
None;

D. Vega-Morales,
None;

J. Esquivel-Valerio,
None;

D. Flores-Alvarado,
None;

D. Treviño-Montes,
None;

E. Torres-López,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/screening-behavior-and-prevalence-of-hepatitis-c-virus-in-mexico/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology